Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.

Aim: To develop a well-tolerated outpatient chemotherapy regimen for hormone-insensitive prostate cancer.

Method: Forty patients received carboplatin 20 mg/m2 by continuous ambulatory infusion with oral etoposide 50 mg/day for 21 days repeated every 6 weeks.

Results: Four patients had a partial response and 16 patients had stable disease.